In the early 2000s, the HOPE study35 found that ramipril, a centrally-acting ACE inhibitor, reduced the risk of stroke by 32% and the risk of fatal stroke by 61%, compared to placebo, despite modest reductions in blood pressure36. Here, ACE is linked to stroke disorder.